General Information of Drug (ID: DM52HUD)

Drug Name
Dexloxiglumide
Synonyms
Dexloxiglumide; 119817-90-2; (R)-4-(3,4-Dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; UNII-69DY40RH9B; CR-2017; 69DY40RH9B; Dexloxiglumidum; Dexloxiglumida; Dexloxiglumide [INN]; Dexloxiglumidum [INN-Latin]; Dexloxiglumida [INN-Spanish]; PubChem16049; AC1Q3MXI; GTPL889; SCHEMBL366142; CHEMBL550781; AC1L24A8; DTXSID50152604; MolPort-006-170-001; CHEBI:135747; ZINC3801027; KS-000007QQ; AKOS000279054; PB12713; DB04856; CC-26372; AJ-45649; AK129760; AS-35102; KB-210163; AX8123879; CS-0054881; FT-0603098; Q-4119
Indication
Disease Entry ICD 11 Status REF
Pancreatic malfunction DC30-DC3Z Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 461.4
Logarithm of the Partition Coefficient (xlogp) 3.9
Rotatable Bond Count (rotbonds) 14
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.7 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.2 hours [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.024% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.18 L/kg [3]
Chemical Identifiers
Formula
C21H30Cl2N2O5
IUPAC Name
(4R)-4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid
Canonical SMILES
CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
InChI
InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1
InChIKey
QNQZBKQEIFTHFZ-GOSISDBHSA-N
Cross-matching ID
PubChem CID
65937
ChEBI ID
CHEBI:135747
CAS Number
119817-90-2
DrugBank ID
DB04856
TTD ID
D0TL7L
INTEDE ID
DR0470

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholecystokinin receptor type A (CCKAR) TTCG0AL CCKAR_HUMAN Inhibitor [4]
Gastrin/cholecystokinin type B receptor (CCKBR) TTVFO0U GASR_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [6]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pancreatic malfunction
ICD Disease Classification DC30-DC3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Gastrin/cholecystokinin type B receptor (CCKBR) DTT CCKBR 6.53E-01 1.00E-03 4.05E-03
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 1.25E-01 -7.02E-02 -2.81E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.83E-01 3.44E-02 7.14E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.84E-06 1.24E-01 6.31E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.75E-01 3.78E-02 1.44E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9.
5 Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
6 Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
7 Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507.